SCHEMBL26964363

SCHEMBL26964363

CCn1ccnc1S(=O)(=O)Nc1cccc2cc(C(C)=O)cnc12

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 15/20 0.43
▸ TDP1 Q9NUW8 3/20 0.40
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ GLO1 Q04760 3/20 0.38
▸ MITF O75030 1/20 0.37
▸ S1PR4 O95977 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ S1PR1 P21453 1/20 0.37
▸ AGTR1 P30556 1/20 0.37
▸ OPRK1 P41145 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ CKS1B P61024 1/20 0.37
▸ SKP2 Q13309 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ PSMD14 O00487 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29800780 1.00 SLC40A1 (0.43) SLC40A1TDP1KMT2AMEN1GLO1
SCHEMBL26964402 0.85 SLC40A1 (0.60) SLC40A1TDP1KMT2AMEN1GLO1
SCHEMBL29800997 0.85 SLC40A1 (0.60) SLC40A1TDP1KMT2AMEN1GLO1
SCHEMBL30925508 0.85 SLC40A1 (0.45) SLC40A1GLO1
SCHEMBL27214324 0.85 SLC40A1 (0.47) SLC40A1TDP1KMT2AMEN1
SCHEMBL30925557 0.85 SLC40A1 (0.47) SLC40A1TDP1KMT2AMEN1
SCHEMBL27214237 0.85 SLC40A1 (0.45) SLC40A1GLO1
SCHEMBL29800797 0.84 SLC40A1 (0.44) SLC40A1TDP1KMT2AMEN1GLO1
SCHEMBL26964396 0.84 SLC40A1 (0.44) SLC40A1TDP1KMT2AMEN1GLO1
SCHEMBL30925463 0.83 SLC40A1 (0.48) SLC40A1TDP1KMT2AMEN1GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 — — EP disclosed
CN-116806218-A Sulfonamide and its use for the treatment of parasitic helminth infections and diseases 新基公司 2023-09-26 — — CN disclosed
WO-2022173727-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885TDP1 4247/4885KMT2A 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback